Orexo (ORX) Stock Overview
A specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ORX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Orexo AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 26.25 |
| 52 Week High | SEK 43.40 |
| 52 Week Low | SEK 12.50 |
| Beta | 0.86 |
| 1 Month Change | -18.35% |
| 3 Month Change | -1.87% |
| 1 Year Change | 65.09% |
| 3 Year Change | 60.06% |
| 5 Year Change | -43.24% |
| Change since IPO | -70.83% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Orexo AB (publ)'s (STO:ORX) 28% Share Price Plunge
Nov 02
There's No Escaping Orexo AB (publ)'s (STO:ORX) Muted Revenues Despite A 29% Share Price Rise
Sep 16Orexo AB (publ) (STO:ORX) Shares Fly 32% But Investors Aren't Buying For Growth
Jun 10Orexo AB (publ) (STO:ORX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Shareholders May Not Be So Generous With Orexo AB (publ)'s (STO:ORX) CEO Compensation And Here's Why
May 02
Zubsolv Litigation Settlement And OX640 Progress Will Secure Stability
Legal settlements and strategic changes stabilize revenue streams, enhancing future planning and financial clarity for Orexo.A Piece Of The Puzzle Missing From Orexo AB (publ)'s (STO:ORX) 105% Share Price Climb
Dec 20Orexo AB (publ) (STO:ORX) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Nov 05Orexo AB (publ) (STO:ORX) Might Not Be As Mispriced As It Looks After Plunging 28%
Aug 02Orexo AB (publ) (STO:ORX) Just Reported Earnings, And Analysts Cut Their Target Price
Jul 20Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward
May 29Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry
Apr 03We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt
Dec 09Shareholder Returns
| ORX | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 1.0% | -2.6% | 1.1% |
| 1Y | 65.1% | -24.4% | 4.7% |
Return vs Industry: ORX exceeded the Swedish Pharmaceuticals industry which returned -24.4% over the past year.
Return vs Market: ORX exceeded the Swedish Market which returned 4.7% over the past year.
Price Volatility
| ORX volatility | |
|---|---|
| ORX Average Weekly Movement | 8.4% |
| Pharmaceuticals Industry Average Movement | 8.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ORX has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ORX's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 72 | Nikolaj Sorensen | www.orexo.com |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis.
Orexo AB (publ) Fundamentals Summary
| ORX fundamental statistics | |
|---|---|
| Market cap | SEK 948.43m |
| Earnings (TTM) | -SEK 403.30m |
| Revenue (TTM) | SEK 26.00m |
Is ORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORX income statement (TTM) | |
|---|---|
| Revenue | SEK 26.00m |
| Cost of Revenue | SEK 14.50m |
| Gross Profit | SEK 11.50m |
| Other Expenses | SEK 414.80m |
| Earnings | -SEK 403.30m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Mar 27, 2026
| Earnings per share (EPS) | -11.48 |
| Gross Margin | 44.23% |
| Net Profit Margin | -1,551.15% |
| Debt/Equity Ratio | 98.5% |
How did ORX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/24 19:35 |
| End of Day Share Price | 2026/02/24 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orexo AB (publ) is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |